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CASE REPORT
AZITHROMYCIN IN THE TREATMENT OF MUCOSAL LEISHMANIASIS
Mario León SILVA-VERGARA, Luciana de Almeida SILVA, Frederico Ricardo Zago MANEIRA, Achilles Gustavo da SILVA & Aluízio PRATA
SUMMARY
This report describes three elderly patients with mucosal form of American tegumentary leishmaniasis associated with chronic
cardiopathy. Due to the known toxicity of classical drugs with activity against Leishmania sp., the patients received three oral courses
of azithromycin therapy in single 500 mg daily dose during ten days, every other month. All lesions healed after the third series. One
of the patients relapsed and a new series of azithromycin was prescribed. Azithromycin may be an alternative drug for the treatment
of leishmaniasis in special situations due to its optimal mucosal and intraphagocyte concentration, single daily posology, high tolerance
and oral administration. The mechanism of this drug on Leishmania sp. is unknown at present.
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The pentavalent antimonial (glucantime®) and sodium stibogluconate
(pentostam®) are drugs of choice for treatment of American tegumentary
leishmaniasis1,5,11. However, the therapeutical response in mucosal forms
is less than that obtained in the cutaneous ulcers and, usually, several
series of antimonial are required for complete clinical healing2,5,8,9,18.
Amphotericin B and pentamidin therapy is the second choice, because
of their toxicity and side effects, although their efficacy is similar to that
of those antimonial by-products14,15,16,20.
Clinical trial with nifurtimox did not show a proper response in the
treatment of the mucosal form of American tegumentary leishmaniasis4,
and the use of pentavalent antimonial associated with pentoxiphylin was
preliminarly effective in patients with mucosal forms, refractory to
antimonial alone7.
Azithromycin, a macrolide by-product of large use in clinical practice,
proved to be experimentally effective against Leishmania major,6 and,
more recently, in open clinical assay, an efficacy of 85% in 20 patients
with leishmaniasis cutaneous forms was reported13. Another study in
Manaus, Brazil, where Leishmania viannia guyanensis is endemic,
showed low efficacy in 26 patients that received this drug (unpublished
data)17.
The present work describes three Brazilian elderly patients with
mucosal leishmaniasis and associated chronical cardiopathy. Due to the
latter condition they received azithromycin.
CLINIC CASE REPORT
Patient 1 - J. P. M., 76 year-old, male, born and resident in São
Francisco de Sales, Minas Gerais, an endemic area of leishmaniasis. He
presented a-four-year ulcerocrusty lesion in the right nostril and bloody
rhinorrhea. Montenegro test was positive (12 mm) and biopsy showed
chronical inflammation with giant cells and granuloma formation,
presenting necrosis areas and mononuclear cells. No leishmania or other
parasites were observed. Because of a previous history of chronical
cardiopathy with heart failure, he received dapsone, and during six months
his lesion was scarred, after, the lesion relapsed and Amphotericin B
was considered. A week later, renal failure developed and this drug
therapy was replaced by low doses of pentavalent antimonial. Within a
few days, clinical and electrocardiographic examination revealed evidence
of antimonial toxicity. The therapy was then discontinued and the patient
received oral azithromycin 500 mg/day, during ten days in three series
every other month. After 120 days, complete healing of the lesion
occurred and at clinical monthly follow-up during one year no relapse
was observed.
Patient 2 - C. J. S., 80 year-old, male, born and resident in
Porteirinha, Minas Gerais, an endemic area of leishmaniasis. He referred
upper and progressive dysphagia for several months. He presented
granulomatous pervasive morula-like lesion, jeopardizing hard and soft
palate, uvula and oropharynx. The lesion was friable and recovered with
a white secretion. Total collapse of the nose had ocurred some years ago
alongside chronical cardiopaty. The histopathological oropharynx lesion
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exam showed amastigotes forms of Leishmania sp into macrophages.
Montenegro test was not performed. Previously, he had irregularly used
pentavalent antimonial, unsuccessfully. He received azithromycin 500
mg/day per oral via, during 10 days in three series every other month.
His lesions evolved for clinical healing, but six months later, relapse
was noticed. Therefore, a new course of azithromycin 500 mg/day during
10 days was required, and remission was observed after three months,
but no follow-up was possible, in spite of several patient recalls.
Patient 3 - E. F. O., 76 year-old, female, born and resident in Araçuaí,
Minas Gerais, an endemic area of leishmaniasis. She presented
ulcerovegetative lesions in the upper lip, hard and soft palate and
oropharynx for eighteen months. She referred upper and progressive
dysphagia, easy bleeding of lesions at minimal traumatisms and weight
loss due to the dysphagia. Clinical exam revealed edema, infiltration
and remarkable protraction of the upper lip, and together with total
collapse of the nares, which had occurred several years ago. Besides,
the patient referred chronical heart failure. Montenegro reaction resulted
positive (14 mm) and lip ulcer biopsy showed chronical inflammation
characterized by perivascular infiltrate with limphocytes, plasmocytes
and histiocytes, and scattered granuloma formation. No amastigotes or
other microrganisms were observed. She received azithromycin 500 mg/
day per oral via, during 10 days, in three courses every other month.
There was complete regression of the lesions in the fourth month of
treatment, normal nourishing and weight. Gain. At 12 months follow-
up she was asymptomatic.
COMMENTS
The treatment of the mucosal form of American tegumentary
leishmaniasis presents some problems regarding the variable response
to antimonials which, like other classical drugs, are all administered by
parenteral via for long periods, and frequently have toxic and side effects,
mainly nephro and cardiotoxicity1,3,11. This fact becomes more evident
in old patients, since they often present cardiopathies and other underlying
diseases. Therefore, contraindications to use these drugs are common
and patient hospitalization is often needed2,7,10. In such cases, other anti-
leishmania therapeutic alternatives become relevant. A favourable clinical
response to azithromycin was described to the cutaneous forms of
American tegumentary leishmaniasis caused by Leishmania viannia
brasiliensis13. The authors treated 20 patients who received 500 mg of
azithromycin daily per oral via for 3, 5 or 10 days or 1,000 mg daily for
two days. Similar courses were repeated when necessary, until full re-
epitelization. Healing time ranged from 60 days in six (30%) of patients
to 120 days in four (20%) of them13.
These results supported the use of azithromycin in these three elderly
patients with chronic mucous lesion suggestive of American tegumentary
leishmaniasis. Besides, they presented chronic cardiopathy and had been
receiving anticongestive therapy for a long time.
Only one of three patients had leishmaniasis diagnosis confirmed
by biopsy. The others presented suggestive clinical lesion together with
a Montenegro positive test and successful response to treatment with
this drug. Nevertheless, other diseases might be considered although no
other microrganisms were seen at histopathological examination.
Despite the early good response, six months later, patient 2 presented
clinical relapse, and a new course with azithromycin healed the lesions.
No side effects were observed in these cases and similar results were
previously reported13. These authors used the same dosage for a short
time. On the other hand, TEIXEIRA (2003)17 observed diarrhea in 60%
of the cases, abdominal pain in 28%, and headache and nauseas in 12%
of 26 patients with cutaneous leishmaniasis receiving azithromycin during
20 days (unpublished data).
A favorable response obtained in these cases may support the anti-
leishmania activity of this macrolide on mucosal leishmaniasis, especially
if considering some outstanding advantages of it: therapeutical response
observed over ten years of its use for several infectious diseases, good
tolerance, high levels of drug into mucosae and phagocytes, and a single
daily oral dose10,12,19.
In accordance with KROLEWIECKI et al.6, the azithromycin’s mode
of action against Leishmania sp is unknown at present. It might be through
either direct effect on parasite or by immune and inflammatory
modulation response. Nevertheless, clinical randomized and controlled
studies are necessary to evaluate the azithromycin efficacy in mucosal
and other clinical presentations of American tegumentary leishmaniasis.
RESUMO
Azitromicina no tratamento da leishmaniose mucosa
O presente relato descreve três pacientes idosos com leishmaniose
mucosa de longa evolução, os quais eram portadores de cardiopatia
crônica. Pela alta freqüência de efeitos secundários e tóxicos dos
medicamentos utilizados no tratamento clássico, esses pacientes
receberam azitromicina. Este medicamento foi administrado pela via
oral, em dose única diária de 500 mg, durante dez dias, em três séries
com intervalo de um mês. Em todos, houve cicatrização das lesões depois
da terceira série. Um dos pacientes apresentou recidiva após seis meses
e uma nova série de azitromicina fez regredir novamente o quadro.
Azitromicina pode ser uma alternativa para o tratamento das
leishmanioses, principalmente pela concentração adequada em mucosas
e nos fagócitos, posologia única diária, boa tolerância e administração
oral.
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